Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study
about
The radiation techniques of tomotherapy & intensity-modulated radiation therapy applied to lung cancerRadiation dose effect in locally advanced non-small cell lung cancerRadiotherapy Techniques and Radiation Pneumonitis: A Lot To A Little Or A Little To A Lot?Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.A phantom model demonstration of tomotherapy dose painting delivery, including managed respiratory motion without motion management.Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinomaAccelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase IIQuantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues.Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy.Intensity-modulated radiation therapy using static ports of tomotherapy (TomoDirect): comparison with the TomoHelical modeChemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancerInvestigation of probabilistic optimization for tomotherapyDose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer.Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer.Accelerated dose escalation with proton beam therapy for non-small cell lung cancer.A new plan quality index for dose painting radiotherapy.Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?Emerging Role of MRI for Radiation Treatment Planning in Lung Cancer.Intensity-modulated radiotherapy might increase pneumonitis risk relative to three-dimensional conformal radiotherapy in patients receiving combined chemotherapy and radiotherapy: a modeling study of dose dumping.Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy.Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques.Treatment outcome for locally advanced non-small-cell lung cancer using TomoDirect plan and its characteristics compared to the TomoHelical plan.Pro: lung cancer in 2011: a time for optimism and investment in new approaches and technologies with a commitment to produce evidence-based data.A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients.Dose-finding designs for trials of molecularly targeted agents and immunotherapies.Investigation of probabilistic optimization for tomotherapy.Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer
P2860
Q26799892-B009B504-0B31-478E-83D9-DA022A9D64C4Q26823043-477C94EA-19E9-4C3B-91DB-80632B637A41Q28068005-9FA5A340-DB41-47DA-AB2C-D4C603C58617Q33688658-147115A2-04E6-4A90-9494-728902897C4CQ33921434-0FC8B815-74F7-41B6-BA93-CE029DB586FDQ34824131-A4B65755-FDEF-491C-BF46-8002BE22CC97Q35997579-4434887E-C778-48AF-9A3B-6A43D5779BE0Q36202855-49C8C1C6-73AA-409A-B896-2974DC06B0A7Q36555940-94B550A2-CFBF-42E3-B7FB-DF15935F94EDQ36814830-B88E8751-D89A-47DB-AF45-2030D8413178Q36989648-D9E8B2A5-DE64-4F4B-9FE7-87E15E3D5B3AQ37122667-F2B8281A-4767-4CBC-AC98-E9613440622EQ37333649-FC77CF46-EED5-4C4C-AD33-656973E53CD1Q37587783-67130532-9CE5-4DAD-AC6F-6D197A35588EQ38201057-951507DA-2473-4951-838D-DEA01EA4126FQ38418854-77937429-5A53-4188-A327-9146D9F83167Q38549486-1CD3926C-4770-4A28-AA9D-1ACF715231BEQ38641099-CCF27209-4DFF-4DA3-9D6B-5EFBF4F50F30Q41915810-5EF5A0AF-1FA4-40FB-AA1C-10EFC39854E1Q43240680-0AF011EF-F5B9-44A2-A2EB-8A2CC59ADEF5Q47362487-D58119D7-DB64-458F-B0A3-482CBD5EAF8DQ48115777-029D8EE3-D73E-4A5E-AB0E-37C78245AA5BQ50597370-10C982F0-D3F8-421C-A51F-EC69914D960CQ53213099-2DB7B5BE-0BB0-4B43-BB91-D9E34480F89BQ53522981-14E901CF-D0B1-4955-BB60-B8AB96C55DC8Q55230920-AA78A482-AF4D-49D7-89C9-CDCFDC7ABA07Q57618162-35EA0E0F-A0AD-4BBB-B4E4-ABB49C7A52F8
P2860
Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Dose escalated, hypofractionat ...... phase I dose escalation study
@ast
Dose escalated, hypofractionat ...... phase I dose escalation study
@en
Dose escalated, hypofractionat ...... phase I dose escalation study
@nl
type
label
Dose escalated, hypofractionat ...... phase I dose escalation study
@ast
Dose escalated, hypofractionat ...... phase I dose escalation study
@en
Dose escalated, hypofractionat ...... phase I dose escalation study
@nl
prefLabel
Dose escalated, hypofractionat ...... phase I dose escalation study
@ast
Dose escalated, hypofractionat ...... phase I dose escalation study
@en
Dose escalated, hypofractionat ...... phase I dose escalation study
@nl
P2093
P2860
P50
P1476
Dose escalated, hypofractionat ...... phase I dose escalation study
@en
P2093
A M Traynor
G M Cannon
J B Adkison
P2860
P304
P356
10.1177/153303460800700605
P577
2008-12-01T00:00:00Z